Scholar Rock Reports Q1 2025 Financial Results

Scholar Rock Holding ( (SRRK) ) has released its Q1 earnings. Here is a breakdown of the information Scholar Rock Holding presented to its investors.

Scholar Rock Holding Corporation is a late-stage biopharmaceutical company focused on developing therapies for serious diseases with high unmet needs, particularly in the neuromuscular disease sector.

In its latest earnings report for the first quarter of 2025, Scholar Rock highlighted significant progress in its spinal muscular atrophy (SMA) program, with the FDA accepting its Biologics License Application (BLA) for apitegromab under priority review. The company is also preparing for a potential U.S. commercial launch in the third quarter of 2025 and anticipates a European launch in 2026.

Key financial metrics from the report indicate a net loss of $74.7 million for the quarter, compared to $56.9 million in the same period last year, driven by increased investment in commercial manufacturing and launch readiness for apitegromab. Scholar Rock’s cash reserves stand at $364.4 million, expected to support operations into 2027. Additionally, the company is advancing its cardiometabolic program and preparing for the first human study of its new myostatin inhibitor, SRK-439.

Scholar Rock is also expanding the development of apitegromab in other severe neuromuscular disorders, including Duchenne muscular dystrophy and facioscapulohumeral muscular dystrophy, with promising preclinical results. The company has strengthened its leadership team to support its transition to a commercial-stage enterprise.

Looking ahead, Scholar Rock remains focused on its strategic priorities, including the anticipated launch of apitegromab and the progression of its clinical trials, as it aims to establish itself as a leader in the neuromuscular disease space.